Copyright
©The Author(s) 2022.
World J Gastroenterol. Sep 7, 2022; 28(33): 4823-4833
Published online Sep 7, 2022. doi: 10.3748/wjg.v28.i33.4823
Published online Sep 7, 2022. doi: 10.3748/wjg.v28.i33.4823
Figure 1 Time based on biologic therapy.
A: Treatment discontinuation; B: Adverse event; C: Infection.
Figure 2 Clinical response and remission rates in elderly inflammatory bowel disease patients treated with different biologicals according to Harvey-Bradshaw Index or Mayo scores.
A: At 3 mo; B: At 6-9 mo; C: After 12-18 mo. CD: Crohn’s disease; UC: Ulcerative colitis; IBD: Inflammatory bowel disease.
- Citation: Hahn GD, LeBlanc JF, Golovics PA, Wetwittayakhlang P, Qatomah A, Wang A, Boodaghians L, Liu Chen Kiow J, Al Ali M, Wild G, Afif W, Bitton A, Lakatos PL, Bessissow T. Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study. World J Gastroenterol 2022; 28(33): 4823-4833
- URL: https://www.wjgnet.com/1007-9327/full/v28/i33/4823.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i33.4823